Literature DB >> 30286466

Utility of Regular Management of Physical Activity and Physical Function in Hemodialysis Patients.

Shohei Yamamoto1, Ryota Matsuzawa2, Yoshifumi Abe1,3, Keika Hoshi4, Kei Yoneki1, Manae Harada1, Takaaki Watanabe1, Takahiro Shimoda1, Yuta Suzuki1, Yusuke Matsunaga5, Kentaro Kamiya1,6, Atsushi Yoshida7, Atsuhiko Matsunaga8,9.   

Abstract

BACKGROUND/AIMS: Several clinical practice guidelines recommend regular assessment of physical activity and physical function as part of routine care in hemodialysis patients. However, there is no clear evidence to support these recommendations. We investigated whether the proportion of attendance at a regular program for management of physical activity and physical function can predict all-cause mortality and cardiovascular events in hemodialysis patients.
METHODS: This retrospective cohort study consisted of 266 hemodialysis patients participating in the management program at least once. Participants were tracked for 3 years after their first attendance at the management program to determine their attendance proportion. The main study outcomes included all-cause mortality and a composite of fatal and nonfatal cardiovascular events.
RESULTS: Median patient age was 64.5 (interquartile range, 56.8 - 72.0) years, 45% were women, and the median time on hemodialysis was 35.5 (interquartile range, 12.0 - 114.3) months at baseline. Sixty-five patients died over a median follow-up of 79 months. The incidence of cardiovascular events was 60 over a median follow-up of 68 months. Even after adjusting for any of the prognostic models, participants who attended ≤ 75% of sessions (n = 140) had higher risks of mortality (hazard ratio (HR), 1.79; 95% confidence interval (CI): 1.00 - 3.36; P = 0.049) and cardiovascular events (HR, 1.84; 95% CI: 1.07 - 3.48; P = 0.03) than those attending > 75% of sessions (n = 126).
CONCLUSION: Hemodialysis patients in whom physical activity and physical function could be assessed more regularly had better prognosis than those with only intermittent assessment.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cardiovascular disease; Chronic kidney disease; Disease management; Exercise; Hemodialysis; Physical activity; Physical function

Mesh:

Year:  2018        PMID: 30286466     DOI: 10.1159/000494016

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Physical activity and its trajectory over time and clinical outcomes in hemodialysis patients.

Authors:  Yuta Suzuki; Ryota Matsuzawa; Keika Hoshi; Yong Mo Koh; Manae Harada; Shohei Yamamoto; Keigo Imamura; Kentaro Kamiya; Atsuhiko Matsunaga
Journal:  Int Urol Nephrol       Date:  2022-01-17       Impact factor: 2.266

2.  Perceived difficulty in activities of daily living and survival in patients receiving maintenance hemodialysis.

Authors:  Takaaki Watanabe; Toshiki Kutsuna; Yuta Suzuki; Manae Harada; Takahiro Shimoda; Shohei Yamamoto; Yusuke Isobe; Keigo Imamura; Yusuke Matsunaga; Ryota Matsuzawa; Kentaro Kamiya; Yasuo Takeuchi; Atsushi Yoshida; Atsuhiko Matsunaga
Journal:  Int Urol Nephrol       Date:  2020-08-14       Impact factor: 2.370

Review 3.  The Role of Physical Activity and Mortality in Hemodialysis Patients: A Review.

Authors:  Fan Zhang; Hui Wang; Weiqiong Wang; Huachun Zhang
Journal:  Front Public Health       Date:  2022-02-17

4.  Associations between dynapenia, cardiovascular hospitalizations, and all-cause mortality among patients on haemodialysis.

Authors:  Shun Yoshikoshi; Shohei Yamamoto; Yuta Suzuki; Keigo Imamura; Manae Harada; Shiwori Osada; Kentaro Kamiya; Atsuhiko Matsunaga
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-08-02       Impact factor: 12.063

5.  Feasibility of long-term intradialytic exercise for older patients receiving hemodialysis: a retrospective single-center study.

Authors:  Keigo Imamura; Yuta Suzuki; Shohei Yamamoto; Ryota Matsuzawa; Manae Harada; Sachi Yamabe; Shiwori Osada; Atsuhiko Matsunaga
Journal:  Int Urol Nephrol       Date:  2021-07-20       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.